Pfizer is pulling a ten-year old product – the monoclonal antibody Mylotarg (gemtuzumab ozogamicin) – from the US market effective mid-October after a postmarketing study showed a higher death rate and no benefit to patients with acute myeloid leukaemia (AML), the US FDA said in a statement.
Once the product's application is withdrawn by autumn, any future use of the anticancer in the US will require